Eagle Pharmaceuticals's total assets for Q2 2023 were $404.82M, a decrease of -2.26% from the previous quarter. EGRX total liabilities were $152.78M for the fiscal quarter, a -10.83% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.